NOV 01, 2019 9:42 PM PDT

C2 combination targets cancer cells more efficiently

Treating cancer is in part so difficult because to be effective, high doses of aggressive drugs must be administered to patients. These treatments often have negative side effects on healthy cells and can also lead to progressive resistance to treatment drugs. That’s why new research published in the journal Cancers showcasing a combination of four anti-cancer components that could be capable of attacking cancerous cells while leaving healthy cells alone is so exciting. The research comes from scientists at the University of Geneva (UNIGE), Switzerland who analyzed 10 substances in 200 different combinations to find the lucky one that they’re calling C2.

C2 consists of four products (tubacin, CI-994, erlotinib and dasatinib) and works by targeting the supernumerary centrosomes that are only found in tumor cells (watch the video above to learn more). By doing so, C2 can provoke cell deaths specific to only tumor cells. "During our in vitro tests, we found that C2 killed up to 20 times more cancer cells than other combinations, while sparing healthy cells," explains Patrick Meraldi, who is a professor in the Department of Cellular Physiology and Metabolism in UNIGE's Faculty of Medicine as well as at the university's Translational Research Centre in Onco-Haematology (CRTOH).

To figure this out, the researchers used a simultaneous validation technique that they developed. "We used a method we developed in our laboratory to test these different combinations simultaneously in vitro on a cancer cell and on a healthy cell. The aim was to directly compare the effects of the treatment on the two types of cells," elaborates Patrycja Nowak-Sliwinska, a professor in the Institute of Pharmaceutical Sciences of Western Switzerland and at UNIGE and CRTOH. "We were able to eliminate the formulas that didn't destroy the diseased cells together with those that also had an impact on the healthy cells.

Scientists hope C2 will serve more effectiively to target cancer cells while leaving healthy cells alone. Photo: Pixabay

This research holds great potential for the future of anti-cancer treatments, particularly when it comes to lowering doses. “The main objective is to reduce the doses of the drugs so we can avoid resistance," explains Nowak-Sliwinska. "That's why we're creating new formulas made up of several low-dose treatments that will help us achieve our goal without inducing any resistance."

The researchers plan to continue their investigations, moving from in vivo testing on mice to monitoring the effects of C2 on the entire body.

Sources: Cancers, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JAN 25, 2020
Cancer
JAN 25, 2020
Unpacking lactate's role in the Warburg effect
In a recent issue of Nature, the findings of one study made a particularly big splash: how and why cancer cells use energy differently than healthy cells. ...
JAN 25, 2020
Cancer
JAN 25, 2020
How HPV might actually defend against skin cancer
New research from scientists at Massachusetts General Hospital features findings that suggest that immunity to certain strains of HPV (human papillomavirus...
JAN 25, 2020
Cancer
JAN 25, 2020
How flavonoids fight against colorectal cancer
New research published in the journal Cancers reports why flavonoids can aid in reducing the risk of colorectal cancer. Flavonoids are compounds found in f...
JAN 25, 2020
Cancer
JAN 25, 2020
Self-renewing blood stem cells give hope for blood disease treatments
New research details how activating a certain protein may be the key to getting hematopoietic stem cells (HSCs) to self-renew. The research comes from scie...
JAN 25, 2020
Drug Discovery & Development
JAN 25, 2020
FDA Approves Ovarian Cancer Drug to Treat Pancreatic Cancer
In 2019, an estimated 46,000 Americans died from pancreatic cancer. Now, the Food and Drug Administration (FDA) has approved Lynparza, an ovarian cancer dr...
JAN 25, 2020
Cancer
JAN 25, 2020
What's the deal with turmeric?
Have you fallen for the turmeric craze? That little orange root that yellows your fingers when you peel it has become very popular recently for its medicin...
Loading Comments...